Acadia Pharmaceuticals Inc $26.61

up +2.63


2/9/2014 04:00 PM  |  NASDAQ : ACAD  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get ACAD Trend Analysis - it has underperformed the S&P 500 by 5%

Partner Headlines

  1. Benzinga's Volume Movers

    Benzinga
  2. ACADIA Pharmaceuticals Announces Stephen Davis As Executive VP, CFO And ...

    Benzinga
  3. 4 Biotech Stocks Worth A Look Ahead Of FDA Approvals

    Benzinga
  4. Morning Lowers for Mar. 5, 2014: XOMA, USU, CSIQ, AUDC, RATE

    Benzinga
  5. Top Stocks Of 2013 Run Gamut: Solar, Drugs, Tech, TV

    IBD
  6. ACADIA Initiates Phase II Trial with Pimavanserin for Alzheimer's Disease ...

    Benzinga
  7. ACADIA Announces Publication of Pivotal Phase III Parkinson's Disease Psychosis ...

    Benzinga
  8. Benzinga's Volume Movers

    Benzinga
  9. Benzinga's Top Pre-Market Gainers

    Benzinga
  10. UPDATE: MLV & Co. Downgrades ACADIA Pharmaceuticals on Valuation

    Benzinga
  11. Benzinga's Top Downgrades

    Benzinga
  12. Acadia Pharma Announces $86M Equity Financing

    Benzinga
  13. Benzinga's Top Pre-Market Losers

    Benzinga
  14. ACADIA Pharmaceuticals Option Volume Spikes

    SchaeffersResearch
  15. Acadia Pharma Rockets Higher on Study Results

    Benzinga
  16. Top Narrow Based Indexes For November 27, 2012

    Benzinga
  17. Stocks Hitting 52-Week Highs

    Benzinga
  18. Morning Market Movers

    Benzinga
  19. Benzinga's Top Pre-Market Gainers

    Benzinga
  20. ACADIA's Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal ...

    Benzinga
  21. ACADIA Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  22. Stocks Hitting 52-Week Highs

    Benzinga
  23. Benzinga's Top Pre-Market Gainers

    Benzinga
  24. Coinstar, Supervalu Among Stocks Down on Above-average Volume Friday

    FoxBusiness
  25. From Earlier, ACADIA Pharmaceuticals Reports Promising Effects of Pimavanserin ...

    Benzinga
  26. Earnings Scheduled For March 6

    Benzinga
Trading Center